The new drug application for CanSinoBIO's adsorbed tetanus vaccine has been accepted
02
Menhycia® obtained Halal decree in Indonesia
02
The DTcP (Infant) vaccine has been granted priority review status by the NMPA
02
The DTcP-Hib-MCV4 combined vaccine has obtained approval for clinical trials
03
CanSinoBIO has signed an exclusive commercialization agreement with Grand Life Science Group
03
CanSinoBIO has signed a collaboration agreement for the supply, manufacturing, and commercialization of MCV4 vaccines with SPIMACO in Saudi Arabia
05
The inhaled TB vaccine has obtained approval for clinical trials in Indonesia
06
iPneucia® obtained NDA approval
09
iPneucia® officially launched
2024
2024
02
Obtained the Acceptance Notice of drug registration applications for the PCV13i、DTcP Infant
03
Initiated Phase Ⅲ clinical trial for Absorbed Tetanus Vaccine
04
Received positive preliminary results from Phase I clinical trials of the PBPV
05
Obtained clinical trial approval of the Hib Vaccine
06
MCV4 has received the drug registration certificate granted in Indonesia
10
VLP-Polio received further funding from the Bill & Melinda Gates Foundation, and initiated clinical trial in Australia (Phase I) and Indonesia (Phase I / II)
10
Collaborate with the National Institutes of Biotechnology Malaysia to develop the multivalent influenza mRNA vaccine
11
Obtained the Acceptance Notice of supplemental application to expand the MCV4‘s applicable population to children aged from 3 months to 6 years old (83 months)
12
Initiated phase Ⅱ/Ⅲ clinical trial for the Tdcp Adolescent and Adult
2023
2023
03
IM & IH of Zoster Vaccine approved for clinical trial in Canada
05
Subscription Agreement with Solution Group Berhad
06
Initiated Phase Ⅰb clinical trial for PBPV
07
Bivalent COVID-19 mRNA vaccine, Tdcp Adolescent and Adult, and Tetanus vaccine approved for clinical trial
津公网安备12011602300399
